Citations

Clear

1575 citation(s) found for "Im, Gene".

The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia
Zheng, Gang , Chen, Ping , Pallavajjalla, Aparna, Haley, Lisa , Gondek, Lukasz P. , Ling, Hua , Marchi, Federico De , Lin, Ming‐Tseh, Gocke, Christopher D. , De Marchi, Federico , Gondek, Lukasz , Dezern, Amy Elizabeth

Mayo Clinic

American Journal of Hematology | July 27, 2019 | Volume: 94 | Issue: 10 | Pages: 1141-1148

10.1002/ajh.25592 | PMID 31350794 Get It

Abstract The diagnostic utility of somatic mutations in the context of cytopenias is unclear: clonal hematopoiesis can be found in healthy individuals, patients with aplastic anemia (AA), clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS). We examined a cohort of 207 well‐characterized cytopenic patients with a 640‐gene next generation sequencing (NGS) panel and compared its diagnostic utility with a “virtual” 41 gene panel. The TET2 , SF3B1 , ASXL1 , and TP53 were the most commonly mutated genes (frequency > 10%). Mutations in the 640‐gene panel show high sensitivity (98.3%) but low specificity (47.6%) for diagnosis of MDS. Notably, mutations of splicing factors and genes in the RAS pathway are relatively specific to MDS. Furthermore, high variant allele frequency (VAF) predicts MDS: when the VAF is set at 20%, the positive predictive value (PPV) for MDS is 95.9%, with a specificity of 95.3%. The presence of two or more somatic mutations with ≥10% VAF showed a PPV of 95.2%. While the “virtual” 41‐gene panel showed a mild decrease in sensitivity (95.7% vs 98.3%), 100% specificity was observed when either VAF was set at ≥20% (100% vs 95.3%), or two or more somatic mutations had VAFs ≥ 10%. Our study shows targeted gene panel sequencing improves the diagnostic approach and accuracy for unexplained cytopenia, with its high sensitivity and high PPV for MDS when applying VAF cutoffs. Furthermore, a 41‐gene panel was shown to have at least comparable performance characteristics to the large 640‐gene panel.
The Clinical Application of Gene Editing: Ethical and Social Issues
Ormond, Kelly E. , Bonham, Vence L. , Hoffman‐Andrews, Lily , Howard, Heidi , Isasi, Rosario , Michie, Marsha , Allyse, Megan , Allyse, Megan A , Bombard, Yvonne , Musunuru, Kiran , Riggan, Kirsten A.

Mayo Clinic

Personalized Medicine | July 23, 2019 | Volume: 16 | Issue: 4 | Pages: 337-350

10.2217/pme-2018-0155 | PMID 31331245 Get It

Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals
Iniesta, Raquel , Campbell, Desmond , Venturini, Cristina , Faconti, Luca , Irvin, Marguerite R. , Johnson, Julie A. , Arnett, Donna K. , Weale, Michael E. , Munroe, Patricia B. , Cruickshank, Kennedy, Lewis, Cathryn M. , Chowienczyk, Phil , Turner, Stephen T. , Arnett, Donna K , Munroe, Patricia B , Singh, Sonal , Cooper‐DeHoff, Rhonda M. , Warren, Helen R. , Padmanabhan, Sandosh , Lewis, Cathryn M

Mayo Clinic

Hypertension | July 22, 2019 | Volume: 74 | Issue: 3 | Pages: 614-622

10.1161/hypertensionaha.118.12177 | PMID 31327267 Get It

Selection of antihypertensive treatment according to self-defined ethnicity is recommended by some guidelines but might be better guided by individual genotype rather than ethnicity or race. We compared the extent to which variation in blood pressure response across different ethnicities may be explained by genetic factors: genetically defined ancestry and gene variants at loci known to be associated with blood pressure. We analyzed data from 5 trials in which genotyping had been performed (n=4696) and in which treatment responses to β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker, thiazide or thiazide-like diuretic and calcium channel blocker were available. Genetically defined ancestry for proportion of African ancestry was computed using the 1000 genomes population database as a reference. Differences in response to the thiazide diuretic hydrochlorothiazide, the β-blockers atenolol and metoprolol, the angiotensin-converting enzyme inhibitor lisinopril, and the angiotensin receptor blocker candesartan were more closely associated to genetically defined ancestry than self-defined ethnicity in admixed subjects. A relatively small number of gene variants related to loci associated with drug-signaling pathways ( KCNK3, SULT1C3, AMH, PDE3A, PLCE1, PRKAG2 ) with large effect size (−3.5 to +3.5 mm Hg difference in response per allele) and differing allele frequencies in black versus white individuals explained a large proportion of the difference in response to candesartan and hydrochlorothiazide between these groups. These findings suggest that a genomic precision medicine approach can be used to individualize antihypertensive treatment within and across populations without recourse to surrogates of genetic structure such as self-defined ethnicity.
Recent advances towards gene therapy for propionic acidemia: translation to the clinic
Barry, Michael A. , Barry, Michael A

Mayo Clinic

Expert Review of Precision Medicine and Drug Development | July 3, 2019 | Volume: 4 | Issue: 4 | Pages: 229-237

10.1080/23808993.2019.1635883 Get It

The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies
Werneburg, Nathan W., Smoot, Rory L. , Werneburg, Nathan, Smoot, Rory L , Gores, Gregory J.

Mayo Clinic

Gene Expression | June 28, 2019 | Volume: 20 | Issue: 1 | Pages: 67-74

10.3727/105221619x15617324583639 | PMID 31253203 Get It

The Hippo pathway and its effector protein YAP (a transcriptional coactivator) have been identified as important in the biology of both hepatocellular carcinoma and cholangiocarcinoma. First identified as a tumor suppressor pathway in Drosophila , the understanding of the mammalian YAP signaling and its regulation continues to expand. In its “on” function, the canonical regulatory Hippo pathway, a well-described serine/threonine kinase module, regulates YAP function by restricting its subcellular localization to the cytoplasm. In contrast, when the Hippo pathway is “off,” YAP translocates to the nucleus and drives cotranscriptional activity. Given the role of Hippo/YAP signaling in hepatic malignancies, investigators have sought to target these molecules; however, standard approaches have not been successful based on the pathways’ negative regulatory role. More recently, additional regulatory mechanisms, such as tyrosine phosphorylation, of YAP have been described. These represent positive regulatory events that may be targetable. Additionally, several groups have identified potentiating feed-forward signaling for YAP in multiple contexts, suggesting other experimental therapeutic approaches to interrupt these signaling loops. Herein we explore the current data supporting alternative YAP regulatory pathways, review the described feed-forward signaling cascades that are YAP dependent, and explore targeting strategies that have been employed in preclinical models of hepatic malignancies.
Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma
Hilal, Talal , Maguire, Alanna , Maguire, Alanna , Rosenthal, Allison C, Hilal, Talal , Kosiorek, Heidi , Rimsza, Lisa M. , Rosenthal, Allison , Maguire, Alanna

Mayo Clinic

Leukemia & Lymphoma | June 27, 2019 | Volume: 60 | Issue: 14 | Pages: 3581-3583

10.1080/10428194.2019.1633637 | PMID 31246148 Get It

FP087DISTINCT GENE EXPRESSION PATTERNS IN EXPERIMENTAL RENAL ARTERY STENOSIS AND ISCHEMIA-REPERFUSION INJURY
Osman, Mazen, Aberger, Simon , Li, Andrea, Taha, Hula, Osman, A. A., Grande, Joseph P. , Li, Andrea, Taha, Hula, Osman, Adam

Mayo Clinic

Nephrology Dialysis Transplantation | June 13, 2019 | Volume: 34 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfz106.fp087 Get It

Treating chronic migraine in CADASIL with calcitonin gene-related peptide receptor antagonism
Badi, Mohammed K. , Goldstein, Eric D , Badi, Mohammed , Goldstein, Eric , Meschia, James F.

Mayo Clinic

Neurology Clinical Practice | June 11, 2019 | Volume: 9 | Issue: 3 | Pages: 277-278

10.1212/cpj.0000000000000651 | PMID 31341718 Get It

Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice
Flores, Rafael R. , Carbo, Lana, Meter, Montina Van, Padilla, Consuelo M. López de , Zhao, Jing , Colangelo, Debora , Yousefzadeh, Negar , Angelini, Luise, Zhang, Lei , Pola, Enrico , Evans, Christopher H. , Gambotto, Andrea , Niedernhofer, Laura J. , Robbins, Paul D. , De Padilla, Consuelo M Lopez, Niedernhofer, Laura J , Robbins, Paul D , Zhang, Lei , Kim, Eun Young , Yousefzadeh, Matthew J., Vo, Nam

Mayo Clinic

The FASEB Journal | June 6, 2019 | Volume: 33 | Issue: 8 | Pages: 9505-9515

10.1096/fj.201900420r | PMID 31170010 Get It

ABSTRACT Previously, we demonstrated that intratumoral delivery of adenoviral vector encoding single‐chain (sc) IL‐23 (Ad.scIL‐23) was able to induce systemic antitumor immunity. Here, we examined the role of IL‐23 in diabetes in nonobese diabetic mice. Intravenous delivery of Ad.scIL‐23 did not accelerate the onset of hyperglycemia but instead resulted in the development of psoriatic arthritis. Ad.scIL‐23–treated mice developed erythema, scales, and thickening of the skin, as well as intervertebral disc degeneration and extensive synovial hypertrophy and loss of articular cartilage in the knees. Immunological analysis revealed activation of conventional T helper type 17 cells and IL‐17–producing γδ T cells along with a significant depletion and suppression of T cells in the pancreatic lymph nodes. Furthermore, treatment with anti–IL‐17 antibody reduced joint and skin psoriatic arthritis pathologies. Thus, these Ad.scIL‐23–treated mice represent a physiologically relevant model of psoriatic arthritis for understanding disease progression and for testing therapeutic approaches.—Flores, R. R., Carbo, L., Kim, E., Van Meter, M., De Padilla, C. M. L., Zhao, J., Colangelo, D., Yousefzadeh, M. J., Angelini, L. A., Zhang, L., Pola, E., Vo, N., Evans, C. H., Gambotto, A., Niedernhofer, L. J., Robbins, P. D. Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice. FASEB J. 33, 9505–9515 (2019). www.fasebj.org
Clinical Trial in Progress: The FLEX Big Data Platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer.
Untch, Sarah, Srkalović, Gordan , Brufsky, Adam , Crozier, Jennifer A. , Habibi, Mehran , Whitworth, Pat W. , Cox, Charles E., D’Abreo, Nina , Audeh, William , Yoder, Erin , Grady, Ian , Brufsky, Adam M

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: TPS3155-TPS3155

10.1200/jco.2019.37.15_suppl.tps3155 Get It

TPS3155 Background: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer. To precisely stratify breast cancers into actionable subgroups, full genome expression data and matching clinical data must be aggregated into a large data set. Such a data set will accelerate research and discovery, especially for smaller patient subsets who are not as widely represented within the current body of literature. Methods: FLEX is a multicenter, prospective, population-based, observational trial for patients with Stage I, II, and III breast cancer. All patients with stage I to III breast cancer who receive MammaPrint, with or without BluePrint on a primary breast tumor are eligible for enrollment. The study’s primary aim is to create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value. Secondary objectives include utilizing the shared study infrastructure to examine and generate hypotheses for targeted subset analyses and/or trials based on full genome expression data. The design of FLEX allows targeted sub-studies and sub-analyses to be added as appendices after the initial baseline study is opened. Patients enrolled in the initial study are also eligible for inclusion in sub-studies where they meet all criteria and additional consent is not required. Additional clinical data will be collected as specified in the appendix protocols. The FLEX collaborative platform allows participating investigators the opportunity to author their own sub-study protocols, as approved by the FLEX Steering Committee of their peers. 13 sub-studies have already been identified and are under development. Eligibility: The study will enroll a minimum of 10000 patients aged ≥18 years with histologically proven invasive stage I-III breast cancer who signed informed consent. Enrollment began April 2017 and 1506 patients have been enrolled. Clinical trial information: NCT03053193.